What to Know About the Cagrilintide Peptide for Weight Loss

For many women, body changes in midlife tend to be surprising, frustrating, and confusing. Your appetite shifts, your sleep becomes more disrupted, and everyday stress takes over—and maintaining your weight can become just one more challenge in a long list (fun, right?). So when peptides like cagrilintide supposedly promise to be even more effective than its very popular weight-loss-med companion, semaglutide, it can feel tempting to dive in headfirst if weight loss is your goal. But there are important safety considerations to keep in mind (which we’ll discuss in more detail below).

Whether you’ve been hearing more about cagrilintide or it’s news to you, here’s what you need to know about what it is, how it works, and how it may fit into a menopause weight loss plan. 

Cagrilintide Peptide: What It Is and Why People Are Talking About It

Cagrilintide is a synthetic (lab-made) medication that is designed to mimic amylin, a hormone made by your pancreas that's released alongside insulin after meals to help signal fullness. As a result, the cagrilintide peptide aims to reduce appetite, boost fullness, and regulate blood sugar.

This pathway is different from what you may have heard about GLP-1s because cagrilintide is not a GLP-1—it's an amylin analog. It works by activating amylin receptors in the brainstem, while GLP-1 drugs work by activating GLP-1 receptors, mainly in the pancreas, brain, and gut. This difference matters because it means cagrilintide can suppress appetite through a separate signaling route than GLP-1s, which is exactly why researchers are largely testing it alongside semaglutide, rather than as a replacement for it.

That’s exactly why some folks are excited about cagrilintide: It may “boost” the effectiveness of semaglutide by activating a second pathway (amylin) that helps you feel full at the same time semaglutide is activating its own (GLP-1), instead of competing for the same one. On its own, cagrilintide might also lead to less uncomfortable side effects like nausea or constipation, but more research is needed to say for sure.

But cagrilintide is still just a research peptide, meaning that even if you find cagrilintide available online, it’s sold by a gray-market retailer who’s circumventing regulations, which can be dangerous. It’s not FDA-approved and Midi clinicians can’t prescribe it. 

Bottom line: While peptide influencers or biohackers might sound so sure about cagrilintide, we don’t have the evidence to prove it's safe and effective for humans quite yet.

Cagrilintide Mechanism of Action (How Cagrilintide Works)

When you eat, your body gets to work processing nutrients—and it sends signals to tell you to stop eating. Your blood sugar rises, triggering beta cells in the pancreas to release amylin and insulin. At that point, amylin works together with leptin (a hunger-regulating hormone released by fat cells) and insulin to make you feel full.

This is where cagrilintide enters the conversation. As an artificial medication, the peptide is designed to mimic the effects of amylin, which makes an impact at a few different points in your body. Specifically, cagrilintide is thought to:

• slow gastric emptying (the movement of food out of the stomach)
• suppress the release of glucagon after eating to reduce blood glucose levels
• activate centers in the brain associated with appetite and reward to reduce how much you eat

What Is CagriSema?

CagriSema is a once-weekly combination therapy of cagrilintide and semaglutide (the two peptides are mixed together in one injection). Currently, CagriSema is an investigational weight loss medication—meaning, it is being actively researched. Although it is not yet available, the manufacturer, Novo Nordisk, filed for FDA approval in December 2025, with FDA review expected in 2026. (Though that won’t stop you from finding people online saying they are already taking it.)

What the Research Says About Weight Loss, Including CagriSema Weight Loss

Overall, cagrilintide appears to produce similar weight loss as semaglutide. However, cagrilintide seems to be less effective for weight loss than the CagriSema combination therapy.

In research that analyzed randomized trials looking at the effects of cagrilintide versus semaglutide, weight loss didn’t meaningfully differ between the two drugs on their own. Another trial found that 2.4 milligrams (mg) of cagrilintide once per week in adults with type 2 diabetes led to an 8% reduction in body weight after 32 weeks, compared with a 5% reduction in body weight on semaglutide. (Earlier research found that a higher 4.5-mg dose of cagrilintide led to 10% weight loss after 26 weeks in adults without diabetes.)

But combining the two peptides and tackling appetite hormones from different but complementary angles appears to be more effective than either peptide alone. A phase 3 trial (the final set of trials before a drug manufacturer seeks FDA approval) in adults with obesity or overweight and at least one obesity-related complication found that CagriSema helped participants lose an average 20.4% of their body weight at 68 weeks of treatment, compared with 3% in the placebo group. About half of the participants who had obesity at the start no longer had weights in the obese range by the end of the trial. 

Meanwhile, a recent meta-analysis found that people taking the CagriSema combination experienced greater weight loss and reductions in waist circumference than either drug alone and much greater than placebo.

With any of these drugs—even those described emphatically as “next-gen weight loss drugs”—there’s no guarantee that everyone will have the same results. And there’s no guarantee you need to wait for these to help you on your wellness journey. There are several research-backed weight loss treatments available right now that many Midi patients do well on, from existing GLP-1s like semaglutide and tirzepatide to lifestyle strategies and more.

Cagrilintide Dosage: Why Trial Dosing Is Not the Same as Personal Dosing

Online, you might find that cagrilintide is available from gray-market retailers in doses that range anywhere from 1 to 10 mg. But it’s important to stress that deciding on a dosage yourself—or based on social media or online forums—is not advisable. Awaiting the final research studies and FDA approval will bring in relevant guidance on dosing and also assure that sourcing is vetted, regulated, safe, and reliable—and not from the unregulated gray market.

Cagrilintide is considered a prescription-only medication, with advice that it is best used safely with clinician guidance and support. At this time, it is not legally prescribable. 

A healthcare professional, such as a Midi clinician, can help determine the right weight loss treatments for you now, such as prescribable weight loss medications like GLP-1s, research-backed supplements, and/or proven lifestyle changes, as there are many highly effective options available currently.

Side Effects and Safety Considerations, Including CagriSema Side Effects

Weight loss medications can come with pretty consistent side effects across the board, including nausea, constipation, vomiting, diarrhea, and abdominal pain, among others. 

Research indicates that CagriSema, semaglutide, and cagrilintide all have a fairly similar rate of negative side effects, though cagrilintide produced notably lower rates of gastrointestinal (GI) disorders. Given the side effect risks, other research suggests that cagrilintide may be an option for people who don’t tolerate GLP-1s well or are especially vulnerable to experiencing nausea and vomiting. It’s not clear exactly why cagrilintide appears to produce less GI side effects, but one theory is that cagrilintide’s appetite-suppressing effect works mainly through brain signaling—but scientists caution that data is still limited here. 

When it comes to CagriSema specifically, a clinical trial found that mild to moderate GI side effects were the most common (think: nausea, vomiting, and diarrhea), which were most likely to occur when the dose was increased. However, these side effects were fairly tolerable: Just 5% more trial participants than people taking a placebo dropped out of treatment due to GI symptoms (8.4% vs. 3.0%). Meanwhile, rarer safety concerns of CagriSema include gallbladder issues, hypoglycemia, or pancreatitis—side effects associated with any GLP-1s. (We’ll learn more once the FDA reviews it.)

It’s crucial to chat with a healthcare professional, such as a Midi clinician to figure out which options are best for your health, rather than trying to map it out on your own. If cagrilintide becomes a viable, prescribable option in the future, a clinician would take your health and the likelihood of side effects into account when deciding on a medication recommendation.

What’s more, if you have diabetes, an existing GI disorder, or other underlying health conditions, you should talk to your clinician first before going on any weight loss medication—and have a clear understanding for what to do if you experience side effects.

Cagrilintide vs. Semaglutide Peptide: How They Compare

In the future, if cagrilintide becomes an available weight-loss medication, should you choose it over semaglutide or other options? 

There’s no one “best” choice, as current studies suggest cagrilintide and semaglutide trigger similar amounts of weight loss, according to a review and meta-analysis in the journal Diabetes, Obesity and Metabolism. Note, too, that other factors come into play when choosing a weight loss medication. A healthcare professional, such as a Midi clinician, will help you sort through insurance coverage, availability, and formulation options. It's important to discuss whether oral, injectable, daily, or weekly dosing fits best into your lifestyle, too, along with a host of other clinical factors.

With all that in mind, the combination of cagrilintide and semaglutide (CagriSema) is anticipated to be a highly effective option in the future—one that’s already generating buzz in the weight loss space. Cagrilintide seems to enhance the effectiveness of semaglutide, turning this into a pumped-up peptide combo. In the same Diabetes, Obesity and Metabolism meta-analysis, CagriSema led to a 7.5% greater weight loss (roughly 17 pounds more) than semaglutide alone.

This data is compelling, but remember, plenty of weight loss medications are available now that people do well on, whether that’s semaglutide by itself, tirzepatide, or other options (more on that below). The right medication for your health involves much more than how much weight it can help you lose. What’s best for your friend or coworker might not be what’s best for you—no matter how much they love the medication they’re on. Your personal goals, how well you tolerate the drug (you should not feel terrible when taking it), and safety are all key for determining which option, if any, suits you best. (Plus, there are now different formulations to discuss, like orals, injectables, and weekly and daily options.)

How Weight Concerns Are Assessed in Midlife Before Medication Enters the Conversation

If you're noticing shifts in your weight or body composition, as so many of us do in midlife, don’t run straight to unregulated peptides or other potentially harmful paths. 

Rather, the best first step is to talk with an empathic, informed clinician—like one at Midi—for a full evaluation of your weight history, waist measurement, bloodwork, metabolic markers, and current medications. Talk with them, too, about any menopause symptoms you’re noticing, your sleep and eating habits, and how you’re managing stress. 

Clinicians will also watch out for underlying health conditions (such as a thyroid disorder) that may affect your weight on the scale. Weight loss medications have a lot of potential benefits, but they’re not do-it-all fixes, and you get the best results when you actually need them. 

Whatever path you and your clinician choose, one thing is for sure: Diet and exercise are important elements of weight management and a healthy lifestyle in general, whether or not you’re on a weight loss drug. Still, these changes can be difficult to make, and some people find that they’re easier and more effective with medication. 

How to Find the Right Treatment Options With a Healthcare Professional

The cagrilintide peptide isn’t an available weight loss treatment option for anyone right now, since it’s still being researched. But don’t fret: Just because something’s new doesn’t make it the best, and a range of weight loss medications and treatment plans are already on hand today, such as: 

• semaglutide (Wegovy, Ozempic)
• tirzepatide (Zepbound, Mounjaro)
• liraglutide (Sazenda)
• orforglipron, a form of oral semaglutide (Foundayo)
• naltrexone and bupropion (Contrave)

A clinician can help match you with the right treatment based on a range of factors, such as your goals, risks to your health, and side-effect history. Lifestyle factors such as nutrition support, strength training, sleep optimization, behavioral changes can all be used together or alongside a prescription medication, if one might benefit you. 

No matter what course of action you choose, talk with a healthcare professional, such as a Midi clinician, about the expectations, timelines, and how to monitor progress so you can stay on track.

When to Seek Care or Urgent Help

If you’re starting a new medication, it’s important to know when to seek emergency care. Red flags to watch for include:

• severe vomiting
• dehydration
• severe abdominal pain
• fainting or signs of low blood sugar

If you’re having bad side effects——such as having trouble eating due to extreme nausea or severe fatigue that interferes with daily function—after trying a new medication or increasing the dose, contact your clinician right away.

Key Takeaways

• Cagrilintide is a synthetic peptide that mimics amylin, the hormone that tells your brain "okay, you're full" and helps keep blood sugar in check.
• Currently, cagrilintide is in the investigational phase, meaning that it’s still being researched in clinical trials. The buzziest use case is CagriSema, which pairs cagrilintide with the GLP-1 drug semaglutide for a potential one-two punch on appetite.
• On its own, cagrilintide may be as effective as semaglutide. But when it teams up with semaglutide as CagriSema, the weight loss results appear to outpace either peptide on its own.
• The catch: no licensed clinician can legally prescribe cagrilintide outside of a clinical trial. Anything you find online today is gray-market territory—not vetted, not regulated, and not worth the risk. 
• The good news? You don't have to wait around, and there are plenty of existing research-backed weight loss treatments. Options like semaglutide and tirzepatide are available now, and pairing them with healthy lifestyle changes can get you real results.

Frequently Asked Questions (FAQs)

What is the best peptide for belly fat loss?

When you lose weight on a synthetic peptide medication, you can expect some belly fat loss. The more dangerous type of abdominal fat is visceral fat because it hugs your organs and is inflammatory. Any of the weight loss drugs mentioned will result in abdominal fat reduction, with those in the GLP-1 category having the highest response rates of currently available options. Research suggests that tirzepatide causes a 40% reduction in visceral fat mass and a 7-inch reduction in waist circumference after 72 weeks.

How often should you take cagrilintide?

The right cagrilintide dosage hasn’t been established yet since it’s still in scientific trials. However, early research suggests that a once-weekly dose of cagrilintide will be needed. (This is the same as injectable semaglutide.) But again, it’s too early to say for sure.

What are the side effects of cagrilintide peptide?

The side effects of cagrilintide are mostly mild to moderate GI symptoms like nausea, vomiting, and diarrhea. It produces similar side effects to GLP-1 medications like semaglutide or GLP-1/GIP drugs like tirzepatide. 

Is cagrilintide worth it?

Not right now. Cagrilintide is still being studied and is not ready for real-world use. The peptide that you can buy online is unregulated and may not be safe or effective for you. 

What is CagriSema?

CagriSema is an investigational amylin-GLP-1 combination medication that includes both cagrilintide and semaglutide. Research is ongoing, but early results suggest that this drug leads to more weight loss than semaglutide alone.